Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804328 | 0.87 | ADORA2B (0.43) | ALDH1A1LMNATP53MAPTMAPK1 | |
| SCHEMBL3831387 | 0.86 | ALDH1A1 (0.40) | ALDH1A1LMNATP53MAPTCYP3A4 | |
| SCHEMBL6350931 | 0.84 | NOTUM (0.44) | ALDH1A1LMNAPOLBMAPTCYP3A4 | |
| SCHEMBL4805021 | 0.83 | ADORA2B (0.46) | ALDH1A1LMNATP53MAPK1KDM4E | |
| SCHEMBL3833080 | 0.83 | SMN1; SMN2 (0.42) | ALDH1A1LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL7004524 | 0.80 | LMNA (0.40) | ALDH1A1LMNAPOLBTP53MAPT | |
| SCHEMBL3871578 | 0.78 | KDM4E (0.39) | ALDH1A1LMNATP53MAPK1KDM4E | |
| SCHEMBL7017390 | 0.72 | DRD2 (0.42) | ALDH1A1LMNAPOLBMAPTCYP3A4 | |
| SCHEMBL6721763 | 0.69 | SLC16A1 (0.59) | CYP3A4 | |
| SCHEMBL3829773 | 0.68 | SLC16A1 (0.39) | ALDH1A1LMNACYP3A4MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153855-A1 | Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents | ASTRAZENECA AB, A SWEDEN CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-7361660-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-04-22 | — | — | US | disclosed |
| EP-1412362-B1 | THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| EP-1107973-B1 | NOVEL THIENO[2,3-d]PYRIMIDINEDIONES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THERAPY | ASTRAZENECA AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-6300334-B1 | DRUGS FOR TREATMENT OF RESPIRATORY SYSTEM DISORDERS | ASTRAZENECA AB (SE) | 2001-10-09 | — | — | US | disclosed |
| EP-1107973-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012514-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | DPYD, TYMP, TYMS | ALDH1A1 236/4885LMNA 4765/4885POLB 687/4885 |
| US-20080153855-A1 | Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents | HRH4, HRH2, HRH3 | ALDH1A1 463/4885LMNA 4873/4885POLB 1897/4885 |
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | ALDH1A1 401/4885LMNA 4569/4885POLB 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.